Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.
We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.
This marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.
Company Details
- Employees
- 51
- Founded
- 2017
- Address
- 99 Park Dr,, Milton,oxfordshire Ox14 4rr,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- greywolftherapeutics.com
- HQ
- Milton, Oxfordshire
Greywolf Therapeutics Questions
Greywolf Therapeutics's website is greywolftherapeutics.com
Greywolf Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/greywolf-therapeutics
Greywolf Therapeutics has
51 employees.
View email and phone details for 51
employees at Greywolf Therapeutics.
Greywolf Therapeutics's industry is
Biotechnology Research
Greywolf Therapeutics's top competitors are
Quell Therapeutics,
Immunocore,
Vertex Pharmaceuticals,
Endlyz Therapeutics,
Molecule To Medicine,
Bicycle Therapeutics,
Pathios Therapeutics,
Adaptimmune,
Melio Bio,
Thirtyfivebio.
Greywolf Therapeutics's categories are Biotechnology Research
Greywolf Therapeutics's founding year is 2017
